Previous Section
Drug Therapy
1. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.
- Author
- Goudar RK; Shi Q; Hjelmeland MD; Keir ST; McLendon RE; Wikstrand CJ; Reese ED; Conrad CA; Traxler P; Lane HA; Reardon DA; Cavenee WK; Wang XF; Bigner DD; Friedman HS; Rich JN;
- Institution
- Department of Pathology, Duke University Medical Center, P.O. Box 2900, Durham, NC 27710, USA.
- Journal
- Mol Cancer Ther. 2005 Jan;4(1):101-12.
- Abstract URL
- Click here to view abstract
2. Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme.
- Author
- Tuettenberg, Jochen; Grobholz, Rainer; Korn, Tobias; Wenz, Frederik; Erber, Ralf; Vajkoczy, Peter;
- Institution
- Department of Neurosurgery, Klinikum Mannheim, Medical Faculty, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany.
- Journal
- J Cancer Res Clin Oncol. 2005 Jan;131(1):31-40. Epub 2004 Sep 28.
- Abstract URL
- Click here to view abstract
3. Response of glioblastomas to EGFR kinase inhibitors.
- Author
- Lassman AB; Abrey LE; Gilbert MR;
- Institution
- Journal
- N Engl J Med. 2006 Feb 2;354(5):525-6; author reply 525-6.
4. Long term responses with cetuximab therapy in glioblastoma multiforme.
- Author
- Belda-Iniesta C; Carpeno Jde C; Saenz EC; Gutierrez M; Perona R; Baron MG;
- Institution
- Translational Oncology Unit CSIC-UAM, Medical Oncology Division, Hospital Universitario La Paz, Universidad Autonoma de Madrid, Madrid, Spain. cbelda@iib.uam.es
- Journal
- Cancer Biol Ther. 2006 Aug;5(8):912-4. Epub 2006 Aug 23.
- Abstract URL
- Click here to view abstract
5. Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
- Author
- Boiardi A; Silvani A; Eoli M; Lamperti E; Salmaggi A; Gaviani P; Fiumani A; Botturi A; Falcone C; Solari A; Filippini G; Di Meco F; Broggi G;
- Institution
- Department of Neuro-oncology, Fondazione IRCSS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, Italy. boiardi@istituto-besta.it
- Journal
- J Neurooncol. 2008 May;88(1):105-13. Epub 2008 Feb 19.
- Abstract URL
- Click here to view abstract
6. Temozolomide in glioblastoma: results of administration at first relapse and in newly diagnosed cases. Is still proposable an alternative schedule to concomitant protocol?
- Author
- Caroli M; Locatelli M; Campanella R; Motta F; Mora A; Prada F; Borsa S; Martinelli-Boneschi F; Saladino A; Gaini SM;
- Institution
- Neurosurgery, Department of Neurological Sciences, Ospedale Maggiore, Mangiagalli e Regina Elena, Fondazione Policlinico, Istituto di Ricovero e Cura a Carattere Scientifico, Via F.co Sforza 35, Milano, 20122, Italy, gfrwca@tin.it.
- Journal
- J Neurooncol. 2007 Mar 15;.
- Abstract URL
- Click here to view abstract
7. Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme.
- Author
- Briceno E; Calderon A; Sotelo J;
- Institution
- Departments of Neuroimmunology and Neurooncology, National Institute of Neurology and Neurosurgery of Mexico, Mexico City 14269, Mexico.
- Journal
- Surg Neurol. 2007 Apr;67(4):388-91.
- Abstract URL
- Click here to view abstract
8. Activity of bortezomib in glioblastoma.
- Author
- Styczynski J; Olszewska-Slonina D; Kolodziej B; Napieraj M; Wysocki M;
- Institution
- Department of Pediatric Hematology and Oncology, Laboratory of Clinical and Experimental Oncology, Nicolaus Copernicus University, Bydgoszcz, Poland. jstyczynski@cm.umk.pl
- Journal
- Anticancer Res. 2006 Nov-Dec;26(6B):4499-503.
- Abstract URL
- Click here to view abstract
Next: Surgical Therapy
